Close Menu

NobleGen

The research team behind the Optipore sequencing strategy adopted by NobleGen Biosciences has published a new proof-of-principle study outlining the steps for fabricating nanopore arrays from solid-state material, as the company itself works to secure Series A financing.

This article has been updated from a previous version to clarify that Wave 80 is evaluating the SPE technology but has not licensed it.
By Ben Butkus

By Julia Karow
This article has been updated to include information about Roche/IBM and Genia.

Noblegen Biosciences has been awarded a $182,000 one-year phase I Small Business Innovation Research grant from the National Human Genome Research Institute to develop its "optipore" sequencing technology, the company disclosed this month.

New Products: Oct 11, 2011

Premium

Illumina has launched several products related to its MiSeq platform, including TruSeq Custom Amplicon Kits, Nextera DNA sample prep kits, and its BaseSpace Cloud Environment for storage and analysis.

The company has automated its DNA conversion process and will shortly install a second-generation prototype nanopore reader.

Paired Ends: Jun 14, 2011

Premium

Wolfgang Oster, Gavriel Meron, Chandra Venkatraman, George Church, Chad Nusbaum, Zhiping Weng, Jorge Leon

"The type of products that can be made with nanopores are very different and can give that revolutionary aspect [to genome sequencing] that PacBio or Ion Torrent can't," Oxford Nanopore's Spike Wilcocks told In Sequence.

Several grantees are affiliated with companies working on new commercial sequencing technologies, including GnuBio, Caerus Molecular Diagnostics, Oxford Nanopore Technologies, Intelligent Bio-Systems, NobleGen Biosciences, and Halcyon Molecular.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.